Clinical and behavioral determinants in pediatric non‐immediate drug hypersensitivity: Low confirmation but persistent avoidance
Pediatric Allergy and Immunology · 2026
DOI: 10.1111/pai.70390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, 2026. Verfasst von Ozge Can Bostan und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Department of Pulmonary Medicine, Division of Allergy and Clinical Immunology, Marmara University, Istanbul, Turkey. Hauptthemen laut MEDLINE: beta Lactam Antibiotics, Drug Hypersensitivity, Hypersensitivity, Delayed. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Non‐immediate drug hypersensitivity reactions (DHRs) in children are frequently overdiagnosed, leading to unnecessary drug avoidance. Evidence regarding predictors of more extensive reactions, drug provocation test (DPT) outcomes, and re‐exposure behavior and avoidance remains limited.
Methods
This retrospective cohort study included 161 children referred for suspected non‐immediate‐type DHRs. Clinical characteristics, reaction features, laboratory findings, and DPT outcomes were collected from medical records. Re‐exposure behavior and avoidance were assessed at 6 and 12 months. Logistic regression was used to identify predictors of more extensive reactions, DPT outcomes, and avoidance of re‐exposure.
Results
Beta‐lactam antibiotics were the most frequently implicated drugs in 154 (95.7%) cases. Generalized cutaneous reactions occurred in 79 (49.1%) and were associated with male sex (OR: 2.70, 95% CI 1.31–5.56, p = .007), concomitant rhinitis/conjunctivitis (OR: 2.41, 1.02–5.71, p = .045), atopic dermatitis (OR: 2.55, 1.05–6.19, p = .038), and symptom onset after >3.5 days of treatment (OR: 3.21, 1.57–6.49, p = .001). DPT was positive in 9.3% of tested children, with no independent predictors of positivity. A mild maculopapular rash as the index reaction independently predicted a negative DPT result. (OR: 6.74, 1.83–24.83, p = .004). At 6 months, 40.7% avoided re‐exposure despite clinical indication, associated with generalized urticaria as the index reaction (OR: 2.60, 1.00–6.72, p = .048) and having received treatment for the reaction (OR: 4.12, 1.08–15.73, p = .038). By 12 months, 86.5% of patients had reused the culprit drug.
Conclusion
Male sex, atopic comorbidities, and later‐onset reactions were associated with an increased risk of more extensive non‐immediate‐type DHRs. Despite low DPT positivity and good re‐exposure tolerance, drug avoidance remains frequent, particularly after treated or generalized reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Department of Pulmonary Medicine, Division of Allergy and Clinical Immunology, Marmara University, Istanbul, Turkey.
- School of Medicine, Department of Pediatric Allergy, Hacettepe University, Ankara, Turkey.
- Department of Allergy and Respiratory Medicine, Iaso Children's Hospital, Athens, Greece.
- Medical School, Child Health Department, University of Ioannina, Ioannina, Greece.
ORCID-Profile: Ozge Can Bostan, Ozge Soyer, Marios Papadopoulos, Sophia Tsabouri
Zitieren
APA
Can Bostan, O., Soyer, O., Papadopoulos, M., & Tsabouri, S. (2026). Clinical and behavioral determinants in pediatric non‐immediate drug hypersensitivity: Low confirmation but persistent avoidance. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70390
Vancouver
Can Bostan O, Soyer O, Papadopoulos M, Tsabouri S. Clinical and behavioral determinants in pediatric non‐immediate drug hypersensitivity: Low confirmation but persistent avoidance. Pediatric Allergy and Immunology. 2026. doi:10.1111/pai.70390
BibTeX
@article{CanBostan2026,
author = {Can Bostan, Ozge and Soyer, Ozge and Papadopoulos, Marios and Tsabouri, Sophia},
title = {Clinical and behavioral determinants in pediatric non‐immediate drug hypersensitivity: Low confirmation but persistent avoidance},
journal = {Pediatric Allergy and Immunology},
year = {2026},
doi = {10.1111/pai.70390}
}
EUVIMED